Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14617832 | 0.87 | CA14 (0.34) | CA14HDAC6 | |
| SCHEMBL2052421 | 0.79 | CA14 (0.33) | CA14HCAR2KEAP1NFE2L2HDAC6 | |
| SCHEMBL2052426 | 0.79 | CA14 (0.33) | CA14HCAR2KEAP1NFE2L2HDAC6 | |
| SCHEMBL14924273 | 0.77 | HCAR2 (0.39) | CA14HCAR2KEAP1NFE2L2HDAC6 | |
| SCHEMBL15156121 | 0.77 | HCAR2 (0.39) | CA14HCAR2KEAP1NFE2L2HDAC6 | |
| SCHEMBL20173486 | 0.77 | SSTR4 (0.31) | HDAC6KDM1AHDAC8 | |
| SCHEMBL15709422 | 0.75 | HCAR2 (0.43) | CA14HCAR2KEAP1NFE2L2 | |
| SCHEMBL15709423 | 0.75 | HCAR2 (0.43) | CA14HCAR2KEAP1NFE2L2 | |
| SCHEMBL20365669 | 0.75 | MLYCD (0.44) | CA14HDAC6 | |
| SCHEMBL23764641 | 0.74 | CA14 (0.36) | CA14HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862722-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2018-01-09 | — | — | US | disclosed |
| US-20150329550-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329550-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2015-11-19 | — | — | US | disclosed |
| US-9138436-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-09-22 | — | — | US | disclosed |
| US-9138436-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-09-22 | — | — | US | disclosed |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| WO-2013010136-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329550-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | CA14 4751/4885HCAR2 4580/4885KEAP1 3166/4885 |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | CA14 4751/4885HCAR2 4580/4885KEAP1 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.